(Z,E)-Farnesol is a cis,trans geometric isomer of farnesol that appears as a minor-to-supporting sesquiterpene alcohol in some floral and rhizome aromatic materials, including greater galangal in the AromaForge archive. Compared with all-trans farnesol, the public literature for this exact isomer is much thinner and skews toward identity, occurrence, and biosynthetic engineering rather than direct bioactivity testing. The record is therefore useful mainly as an isomer-specific chemistry marker with honest evidence gaps around standalone safety and mechanism data.
Chemical identity and composition
PubChem CID 1549108 resolves this constituent as (2-cis,6-trans)-Farnesol with formula C15H26O, InChIKey CRDAMVZIKSXKFV-PVMFERMNSA-N, and synonyms including (2Z,6E)-Farnesol, (Z,E)-Farnesol, cis,trans-Farnesol, and CAS 3790-71-4. The public IFRA Farnesol standard also lists 3790-71-4 within the broader farnesol restriction scope. In the local archive, this exact ID is a supporting marker in greater galangal rhizome oil at 3.8% in the cited Malaysia rhizome profile used by the oil record.
Aroma and practical use
- Use the recorded floral, green, woody, delicate descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2013 Metabolic Engineering paper reported biosynthetic production of Z,E-farnesol in engineered E. coli, reaching 115.6 mg/L with a fusion FPP synthase designed to favor Z,E-FPP over E,E-FPP.
A 2013 Metabolic Engineering paper reported biosynthetic production of Z,E-farnesol in engineered E. coli, reaching 115.6 mg/L with a fusion FPP synthase designed to favor Z,E-FPP over E,E-FPP.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The greater galangal rhizome profile used locally identifies (Z,E)-farnesol at 3.8% as one of the recurrent sesquiterpene-alcohol markers supporting the archive's cineole / sesquiterpene chemotype model.
The greater galangal rhizome profile used locally identifies (Z,E)-farnesol at 3.8% as one of the recurrent sesquiterpene-alcohol markers supporting the archive's cineole / sesquiterpene chemotype model.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
recorded reference · IFRA Standard, Farnesol (Amendment 49, 2020) - Category 5A (leave-on skin) maximum acceptable concentration in finished product, 0.29%; in-scope CAS includes 3790-71-4 ((Z,E)-farnesol); basis: dermal sensitizationThe public IFRA Farnesol standard covers CAS 3790-71-4 within the broader farnesol restriction scope, so this isomer inherits a fragrance-safety context even though most public safety discussion is not separated cleanly by geometry.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
No isolated human clinical safety or efficacy literature specific to (Z,E)-farnesol was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
biosynthetic reporter for z e fpp
In metabolic-engineering work, Z,E-farnesol serves as the alcohol readout of Z,E-farnesyl diphosphate production, highlighting noncanonical sesquiterpene stereochemistry rather than a validated human-use mechanism.
This experimental finding does not establish benefit, dose or safety in people using this blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (4)
- Direct constituent-specific bioactivity studies for isolated (Z,E)-farnesol were sparse in the reviewed public sources.
- Most modern farnesol safety and activity literature pools isomers rather than separating the Z,E form cleanly.
- A stronger public occurrence paper with fully readable body text for the galangal profile was not verified in this pass.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.